Motif Bio PLC Chief Medical Officer presents at congress in USA

TIDMMTFB

Motif Bio PLC

26 August 2016

Motif Bio plc

("Motif Bio" or the "Company")

Chief Medical Officer to present at the World Anti-Microbial Resistance Congress

Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that Dr. David Huang, Chief Medical Officer, will lead a panel discussion at the World Anti-Microbial Resistance Congress in Washington, USA on 9 September 2016.

The discussion is titled: 'In-licensing: Addressing the deficiencies in the original development program to develop a unique non-combination anti-infective'

For further information on the conference please see:

http://www.terrapinn.com/conference/antimicrobial-resistance-congress-usa/index.stm

For further information please contact:

 
 Motif Bio plc                          info@motifbio.com 
 Graham Lumsden (Chief 
  Executive Officer) 
 
 Walbrook PR Ltd. (FINANCIAL      +44 (0) 20 7933 8780 or 
  PR & IR)                        motifbio@walbrookpr.com 
 Paul McManus                        Mob: +44 (0)7980 541 
                                                      893 
 Mike Wort                           Mob: +44 (0)7900 608 
                                                      002

About Motif Bio

Motif Bio plc is a clinical stage biopharmaceutical company engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), infections which are often caused by MRSA. We are currently enrolling and dosing patients in two global Phase 3 clinical trials with an IV formulation of iclaprim, for the treatment of ABSSSI.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAAKPDDKBKBQFB

(END) Dow Jones Newswires

August 26, 2016 02:00 ET (06:00 GMT)

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024